Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT02649387Phase 2Completed
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
PrincipalinvestigatorStart date: 2016-02-08

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sikander Ailawadhi, M.D.

Mayo Clinic

Moderately Similar
6 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more

Worked with same sponsors:

Mayo Clinic
Collaborated on 1 trial
Similarity Score44%

Robert Bociek, MD

University of Nebraska

Moderately Similar
2 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Srdan Verstovsek

M.D. Anderson Cancer Center

Moderately Similar
4 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Ryotaro Nakamura

City of Hope Medical Center

Moderately Similar
10 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Tait Shanafelt

Mayo Clinic

Moderately Similar
3 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more

Worked with same sponsors:

Mayo Clinic
Similarity Score30%

Stephen Spurgeon

OHSU Knight Cancer Institute

Moderately Similar
3 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Jennifer Woyach, MD

The Ohio State University Comprehensive Cancer Center

Moderately Similar
1 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Moderately Similar
11 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Shuo Ma, MD, PhD

Northwestern University

Moderately Similar
3 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Sonali Smith

University of Chicago

Moderately Similar
3 trials

Shared therapeutic areas:

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Similarity Score30%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT02649387Phase 2PrincipalInvestigator

Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic Leukemia+1 more
Completed

All 1 trials loaded